Hemolytic anemia medical therapy
|
Hemolytic anemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hemolytic anemia medical therapy On the Web |
|
American Roentgen Ray Society Images of Hemolytic anemia medical therapy |
|
Risk calculators and risk factors for Hemolytic anemia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Overview
Treatment depends on the cause and nature of the breakdown.
Medical Therapy
- Corticosteroids: The cornerstone of therapy for warm autoimmune hemolytic anemia is steroids. Steroids are the first-line therapy for induction of a response. The initial regimen of steroids is usually prednisone 1-1.5 mg/kg PO daily, to be continues for 1-3 weeks until the hemoglobin increases to 10 g/dl. Steroids are then rapidly tapered. Steroids are effective in approximately 70-85% of patients (PMC4181250). The benefits of steroids are that they can induce a remission within a relatively quick timeframe, such as days to weeks. The use of steroids is meant for short-term, as there can be many adverse effects from long-term systemic steroid use. These adverse effects include immunosuppression with risk for infections, bone loss, muscle loss, weight gain, cataracts, and glaucoma.
- Splenectomy: This is a second-line therapy option and is typically done only if there is non-response to steroids. The response rate to splenectomy is usually 60-70%. Given that this is a surgery, the risks and benefits must be carefully weighed, as surgical interventions typically have higher risks than medication interventions. Splenectomy carries an inherent surgical risk in addition to the risk for infections from encapsulated organisms, such as Neisseria meningitides, Streptococcus pneumoniae, and Hemophilus influenzae. Patients who plan to undergo splenectomy should be vaccinated prior to the surgery. In the current era, the surgical risk of splenectomy is likely lower than in the prior decades, as laparoscopic and minimally invasive approaches are used.
- Rituximab: This is a monoclonal antibody that targets the CD20 antigen on B cells. The basis for the use of rituximab in hemolytic anemia is that B cells are producing antibodies that bind to red blood cell membranes and cause hemolysis. Rituximab binds to B cells and eliminates the B cells by antibody-dependent cell-mediated cytotoxicity. This medication is considered a biologic agent, as it is derived from mice. Risks of rituximab include infusion reaction (during the initial administration of the agent), hepatitis B reactive, and opportunistic infections, such as progressive multifocal leukoencephalopathy. The benefits of rituximab are that there are no steroid-specific adverse effects, such as bone loss, cataracts, glaucoma, stress ulcers, muscle loss, and weight gain.